Temsirolimus: all 177 studies that test it
Page 1 of 2. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the KneeRecruitingNCT04433572Phase 3
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNCT04199026Not applicable
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of RecurrenceRecruitingNCT02446431Early Phase 1
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaActive, not recruitingNCT02567435Phase 3Results posted
- Personalized Targeted Inhibitors Treatment in Renal Cell CancerTerminatedNCT02560012Phase 2Results posted
- Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell TumorsCompletedNCT01946529Phase 2Results posted
- Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder CancerCompletedNCT01827943Phase 2Results posted
- Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerCompletedNCT01827267Phase 2Results posted
- Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed NeuroblastomaCompletedNCT01767194Phase 2Results posted
- Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular CarcinomaCompletedNCT01687673Phase 2Results posted
- Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCompletedNCT01646021Phase 3Results posted
- Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
- A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins LymphomaCompletedNCT01614197Phase 1Results posted
- Phase II Study of Alternating Sunitinib and TemsirolimusCompletedNCT01517243Phase 2Results posted
- Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)CompletedNCT01392183Phase 2Results posted
- Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular LymphomaCompletedNCT01381692Phase 1/2Results posted
- Combination Trial of Pimasertib (MSC1936369B) With TemsirolimusTerminatedNCT01378377Phase 1Results posted
- A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib ProtocolsTerminatedNCT01369433Not applicableResults posted
- Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01281917Phase 2Results posted
- Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory RhabdomyosarcomaCompletedNCT01222715Phase 2Results posted
- Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By SurgeryCompletedNCT01206140Phase 2Results posted
- Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian CancerCompletedNCT01196429Phase 2Results posted
- Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell LymphomaCompletedNCT01180049Phase 4Results posted
- Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IVTerminatedNCT01166126Phase 2Results posted
- Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast CancerCompletedNCT01111825Phase 1/2Results posted
- Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to ChemotherapyCompletedNCT01083368Phase 1/2Results posted
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaCompletedNCT01076543Phase 1/2Results posted
- Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the UterusTerminatedNCT01061606Phase 2Results posted
- Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant GliomaCompletedNCT01051557Phase 1/2Results posted
- Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By SurgeryCompletedNCT01026792Phase 2Results posted
- Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate CancerCompletedNCT01026623Phase 1/2Results posted
- Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid CancerCompletedNCT01025453Phase 2Results posted
- Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate CancerTerminatedNCT01020305Phase 1/2Results posted
- Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone SarcomaCompletedNCT01016015Phase 2Results posted
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
- Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell CarcinomaTerminatedNCT01009203Phase 2Results posted
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver CancerCompletedNCT00980460Phase 3Results posted
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerActive, not recruitingNCT00977574Phase 2Results posted
- Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent SarcomaCompletedNCT00949325Phase 1/2Results posted
- Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung CancerTerminatedNCT00921310Phase 1/2Results posted
- Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer PatientsCompletedNCT00919035Phase 2Results posted
- Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate CancerTerminatedNCT00887640Phase 2Results posted
- Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer PatientsTerminatedNCT00877773Phase 1/2Results posted
- Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid TumorsCompletedNCT00838539Phase 1Results posted
- Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk NeuroblastomaTerminatedNCT00808899Phase 2Results posted
- Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell CarcinomaCompletedNCT00782275Phase 2Results posted
- Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00775593Phase 2Results posted
- Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00723255Phase 2Results posted
- Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerCompletedNCT00699491Phase 1/2Results posted
- Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsCompletedNCT00631371Phase 3Results posted
- Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell CarcinomaCompletedNCT00494091Phase 2Results posted
- Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple MyelomaCompletedNCT00483262Phase 1/2Results posted
- Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line SunitinibCompletedNCT00474786Phase 3Results posted
- Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00429793Phase 2Results posted
- Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT00397982Phase 2Results posted
- Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney CancerCompletedNCT00378703Phase 2Results posted
- Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00376688Phase 2Results posted
- Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00335764Phase 1/2Results posted
- CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00290472Phase 2Results posted
- Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By SurgeryCompletedNCT00281957Phase 2Results posted
- Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)CompletedNCT00117598Phase 3Results posted
- CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00112840Phase 1/2Results posted
- CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109967Phase 2Results posted
- Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid TumorsCompletedNCT00106353Phase 1/2Results posted
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
- Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial CancerCompletedNCT00072176Phase 2Results posted
- Study Evaluating Interferon And CCI-779 In Advanced Renal Cell CarcinomaCompletedNCT00065468Phase 3Results posted
- Study Evaluating Temsirolimus (CCI-779) In Breast NeoplasmsCompletedNCT00062751Phase 2Results posted
- Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGGTerminatedNCT05773326Early Phase 1
- Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal RevascularizationTerminatedNCT03942601Phase 2
- NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingNCT02389309Phase 1
- Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS TumoursCompletedNCT02343718Phase 1
- Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT02215720Phase 1
- POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With TemsirolimusCompletedNCT02093598Phase 2
- Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaWithdrawnNCT01851408Phase 2
- STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT01653067Phase 2
- Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by SurgeryCompletedNCT01625156Phase 1
- Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic LeukemiaCompletedNCT01611116Phase 2
- Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerCompletedNCT01596140Phase 1
- Temsirolimus as Second-line Therapy in HCCStatus unknownNCT01567930Phase 2
- Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
- Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphomaCompletedNCT01535989Phase 1
- Temsirolimus in Combination With Metformin in Patients With Advanced CancersTerminatedNCT01529593Phase 1
- Study of Axitinib and Temsirolimus in Solid TumorsCompletedNCT01529138Phase 1
- Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial CarcinomaCompletedNCT01460979Phase 2
- Temsirolimus In Phase 0CompletedNCT01417065Early Phase 1
- Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell CarcinomaCompletedNCT01404104Not applicable
- Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaCompletedNCT01403415Phase 1
- A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare TumoursActive, not recruitingNCT01396408Phase 2
- Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).CompletedNCT01389427Phase 1/2
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT01375829Phase 1
- Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)WithdrawnNCT01335074Phase 1/2
- Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular CancerWithdrawnNCT01281943Phase 2
- Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell CarcinomaTerminatedNCT01264341Phase 2
- Hepatocellular Carcinoma (HCC)_Torisel_CompletedNCT01251458Phase 1/2
- Temsirolimus-RCC-imagingStatus unknownNCT01246817Phase 2
- CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS)CompletedNCT01206036Phase 1/2